Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human parainfluenza virus type 3 Ebola vaccine
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranasal, Inhalation
01
Overview
The human parainfluenza virus type 3 (HPIV3) Ebola vaccine is an experimental live-attenuated viral vector vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID). It is engineered using a recombinant HPIV3 backbone to express the glycoprotein (GP) of the Zaire ebolavirus. Unlike many other Ebola vaccines that are administered intramuscularly, this candidate is specifically designed for intranasal or aerosol administration to target the respiratory mucosa, aiming to elicit a robust local immune response in addition to systemic immunity. The HPIV3 vector is typically attenuated to prevent disease while remaining capable of limited replication to enhance immunogenicity. This vaccine platform is being evaluated for its potential to provide a needle-free alternative for Ebola prevention and to potentially block transmission through respiratory routes.
- Other names
- HPIV3-vectored Ebola vaccineHPIV-3-vectored Ebola vaccineHPIV 3-vectored Ebola vaccine
02
Targets
Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on human parainfluenza virus type 3 Ebola vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human parainfluenza virus type 3 Ebola vaccine.